Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05380323 · ClinicalTrials.gov registry record · Phase 1
A Study of LY3541105 in Healthy and Overweight Participants
A Phase 1 study, sponsored by Eli Lilly and Company.
- Completed
- Registry status
- Phase 1
- Development phase
- 206
- Enrollment target
NCT05380323 is a Phase 1 study that has completed, run by Eli Lilly and Company. The registered enrollment target is 206 participants.
The verdict
NCT05380323, a Phase 1 study, has completed, sponsored by Eli Lilly and Company.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 206 participants
- Enrollment target
Study Summary
The main purpose of this study is to evaluate the safety and tolerability of LY3541105 in healthy and overweight participants. Blood tests will be performed to check how much LY3541105 gets into the bloodstream and how long it takes the body to eliminate it. The study will also evaluate the effects of LY3541105 on body weight and assess safety and tolerability of LY3541105. This is a 3-part study and may last up to 15, 26 and 24 weeks for each participant and may include up to 7, 15 and 16 visits in parts A, B and C, respectively.
Interventions
- DRUG Placebo
- DRUG LY3541105
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 206 participants |
| Start Date | 2022-05-10 |
| Est. Completion | 2024-08-27 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05380323
The ClinicalTrials.gov registry entry for NCT05380323 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 206 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Eli Lilly and Company, which has 1,341 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT05380323 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05380323 about?
NCT05380323 is a clinical study titled "A Study of LY3541105 in Healthy and Overweight Participants". The main purpose of this study is to evaluate the safety and tolerability of LY3541105 in healthy and overweight participants. Blood tests will be performed to check how much LY3541105 gets into the bloodstream and how long it takes the body to eliminate it. The study will also evaluate the effects ...
What is the current status of trial NCT05380323?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 206 participants. The study started on 2022-05-10. Estimated completion is 2024-08-27.
What interventions are being tested in trial NCT05380323?
The interventions under investigation include: Placebo (DRUG), LY3541105 (DRUG).
Who is sponsoring clinical trial NCT05380323?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.